Top

BMC Psychiatry

Published in:

Open Access 01-12-2021 | Schizophrenia | Research

BDNF, GDNF, NGF and Klotho levels and neurocognitive functions in acute term of schizophrenia

Authors: Betul Aslan Turkmen, Esra Yazici, Derya Guzel Erdogan, Mehmet Akif Suda, Ahmet Bulent Yazici

Published in: BMC Psychiatry | Issue 1/2021

Abstract

Background

Klotho and its relationship with neurotrophic factors and cognition in schizophrenia has not yet been investigated. In this study, the hypothesis that the blood serum levels of BDNF, GDNF, NGF and Klotho in schizophrenia patients and healthy controls would be related to cognitive functions was investigated.

Methods

In this study, two groups were assessed: schizophrenia patients (case group) who were hospitalised in the Psychiatry Clinic of Sakarya University Training and Research Hospital and healthy volunteers (control group). The patients were evaluated on the 1st and 20th days of their hospitalisation with the Positive and Negative Syndrome Scale (PANSS), the Brief Psychiatric Rating Scale (BPRS), the General Assessment of Functioning Scale (GAF) and the Clinical Global Impression Scale (CGI). For cognitive assessment, both groups were evaluated with the Wechsler Memory Scale-Visual Production Subtest (Wechsler Memory Scale III-Visual Reproduction Subtest) and the Stroop test.

Results

BDNF, GDNF, NGF and Klotho levels were lower in schizophrenia patients than in healthy controls. In the schizophrenia patients, on the 20th day of treatment, there was a statistically significant increase in BDNF compared to the 1st day of treatment. BDNF, GDNF and Klotho showed positive correlations with some cognitive functions in the healthy controls. BDNF, GDNF, NGF and Klotho levels were intercorrelated and predictive of each other in both groups.

Conclusion

This study suggests a relationship between cognitive functions, neurotrophic factors and Klotho. Most of the results are the first of their kind in the extant literature, while other results are either similar to or divergent from those generated in previous studies. Therefore, new, enhanced studies are needed to clarify the role of Klotho and neurotrophic factors in schizophrenia.

Available only for authorised users

Kalkstein S, Hurford I, Gur RC. Neurocognition in schizophrenia. Curr Top Behav Neurosci. 2010;4:373–90. https://doi.org/10.1007/7854_2010_42.CrossRefPubMed

Dennerstein L, Lehert P, Bäckström TC, Heinemann K. Premenstrual symptoms -- severity, duration and typology: an international cross-sectional study. Menopause Int. 2009;15(3):120–6. https://doi.org/10.1258/mi.2009.009030.CrossRefPubMed

Millan MJ, Fone K, Steckler T, Horan WP. Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur Neuropsychopharmacol. 2014;24(5):645–92. https://doi.org/10.1016/j.euroneuro.2014.03.008.CrossRefPubMed

Voss P, Thomas ME, Guercio GD, de Villers-Sidani E. Dysregulation of auditory neuroplasticity in schizophrenia. Schizophr Res. 2018;207:3–11. https://doi.org/10.1016/j.schres.2018.04.025.CrossRefPubMed

Fiş NP, Berkem M. Development of neurotransmitter systems and their reflections on psychopathology. Klin Psikofarmakoloji Bul. 2009;19(3):311-320.

Aoyama Y, Mouri A, Toriumi K, Koseki T, Narusawa S, Ikawa N, et al. Clozapine ameliorates epigenetic and behavioral abnormalities induced by phencyclidine through activation of dopamine D1 receptor. Int J Neuropsychopharmacol. 2014;17(5):723–37. https://doi.org/10.1017/S1461145713001466.CrossRefPubMed

Yazici E, Mutu Pek T, Guzel D, Yazici AB, Akcay Ciner O, Erol A. Klotho, vitamin D and homocysteine levels during acute episode and remission periods in schizophrenia patients. Nord J Psychiatry. 2019;73(3):178–84. https://doi.org/10.1080/08039488.2019.1582697.CrossRefPubMed

Lu B. BDNF and activity-dependent synaptic modulation. Learn Mem. 2003;10(2):86–98. https://doi.org/10.1101/lm.54603.CrossRefPubMedPubMedCentral

Grillo RW, et al. Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics. J Psychiatr Res. 2007;41(1–2):31–5. https://doi.org/10.1016/j.jpsychires.2006.01.005.CrossRefPubMed

10.

Ikeda Y, Yahata N, Ito I, Nagano M, Toyota T, Yoshikawa T, et al. Low serum levels of brain-derived neurotrophic factor and epidermal growth factor in patients with chronic schizophrenia. Schizophr Res. 2008;101(1–3):58–66. https://doi.org/10.1016/j.schres.2008.01.017.CrossRefPubMed

11.

Toyooka K, Asama K, Watanabe Y, Muratake T, Takahashi M, Someya T, et al. Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res. 2002;110(3):249–57. https://doi.org/10.1016/S0165-1781(02)00127-0.CrossRefPubMed

12.

Zhang XY, Zhou DF, Wu GY, Cao LY, Tan YL, Haile CN, et al. BDNF levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic schizophrenia. Neuropsychopharmacology. 2008;33(9):2200–5. https://doi.org/10.1038/sj.npp.1301619.CrossRefPubMed

13.

Xiu MH, Hui L, Dang YF, de Hou T, Zhang CX, Zheng YL, et al. Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics. Prog Neuro-Psychopharmacol Biol Psychiatry. 2009;33(8):1508–12. https://doi.org/10.1016/j.pnpbp.2009.08.011.CrossRef

14.

Rizos EN, Papadopoulou A, Laskos E, Michalopoulou PG, Kastania A, Vasilopoulos D, et al. Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics. World J Biol Psychiatry. 2010;11(2 Pt 2):251–5. https://doi.org/10.3109/15622970802182733.CrossRefPubMed

15.

Gama CS, Andreazza AC, Kunz M, Berk M, Belmonte-de-Abreu PS, Kapczinski F. Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder. Neurosci Lett. 2007;420(1):45–8. https://doi.org/10.1016/j.neulet.2007.04.001.CrossRefPubMed

16.

Reis HJ, Nicolato R, Barbosa IG, Prado PHT, Romano-Silva MA, Teixeira AL. Increased serum levels of brain-derived neurotrophic factor in chronic institutionalized patients with schizophrenia. Neurosci Lett. 2008;439(2):157–9. https://doi.org/10.1016/j.neulet.2008.05.022.CrossRefPubMed

17.

Niitsu T, Shirayama Y, Matsuzawa D, Shimizu E, Hashimoto K, Iyo M. Association between serum levels of glial cell-line derived neurotrophic factor and attention deficits in schizophrenia. Neurosci Lett. 2014;575:37–41. https://doi.org/10.1016/j.neulet.2014.05.034.CrossRefPubMed

18.

Ye F, Zhan Q, Xiao W, Sha W, Zhang X. Altered serum levels of glial cell line-derived neurotrophic factor in male chronic schizophrenia patients with tardive dyskinesia. Int J Methods Psychiatr Res. 2018;27(4):e1727. https://doi.org/10.1002/mpr.1727.CrossRefPubMedPubMedCentral

19.

Rodrigues-Amorim D, Rivera-Baltanás T, Bessa J, Sousa N, Vallejo-Curto MC, Rodríguez-Jamardo C, et al. The neurobiological hypothesis of neurotrophins in the pathophysiology of schizophrenia: a meta-analysis. J Psychiatr Res. 2018;106:43–53. https://doi.org/10.1016/j.jpsychires.2018.09.007.CrossRefPubMed

20.

Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390(6655):45–51. https://doi.org/10.1038/36285.CrossRefPubMed

21.

Kuro-o M. Klotho and betaKlotho. Adv Exp Med Biol. 2012;728:25–40. https://doi.org/10.1007/978-1-4614-0887-1_2.CrossRefPubMed

22.

Kimura T, Shiizaki K, Akimoto T, Shinzato T, Shimizu T, Kurosawa A, et al. The impact of preserved Klotho gene expression on antioxidative stress activity in healthy kidney. Am J Physiol Ren Physiol. 2018;315(2):F345–52. https://doi.org/10.1152/ajprenal.00486.2017.CrossRef

23.

Nagai T, Yamada K, Kim HC, Kim YS, Noda Y, Imura A, et al. Cognition impairment in the genetic model of aging klotho gene mutant mice: a role of oxidative stress. FASEB J. 2003;17(1):50–2. https://doi.org/10.1096/fj.02-0448fje.CrossRefPubMed

24.

Man L, Lv X, du XD, Yin G, Zhu X, Zhang Y, et al. Cognitive impairments and low BDNF serum levels in first-episode drug-naive patients with schizophrenia. Psychiatry Res. 2018;263:1–6. https://doi.org/10.1016/j.psychres.2018.02.034.CrossRefPubMed

25.

Xiong JW, Zhan JQ, Luo T, Chen HB, Wan QG, Wang Y, et al. Increased plasma level of longevity protein klotho as a potential indicator of cognitive function preservation in patients with schizophrenia. Front Neurosci. 2020;14:610. https://doi.org/10.3389/fnins.2020.00610.CrossRefPubMedPubMedCentral

26.

Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–76. https://doi.org/10.1093/schbul/13.2.261.CrossRefPubMed

27.

Karakaş S, Karakaş HM. Yönetici işlevlerin ayrıştırılmasında multidisipliner yaklaşım: Bilişsel psikolojiden nöroradyolojiye. Klinik Psikiyatri. 2000;3(4):215–22.

28.

Soykan C. Institutional differences and case typicality as related to diagnosis system severity, prognosis and treatment, in psychology. Ankara: Middle East Technical University; 1990.

29.

Leucht S, et al. Dose equivalents for antipsychotic drugs: the DDD method. Schizophr Bull. 2016;42(Suppl 1):S90–4. https://doi.org/10.1093/schbul/sbv167.CrossRefPubMedPubMedCentral

30.

Leucht S, Crippa A, Siafis S, Patel MX, Orsini N, Davis JM. Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia. Am J Psychiatry. 2020;177(4):342–53. https://doi.org/10.1176/appi.ajp.2019.19010034.CrossRefPubMed

31.

Wechsler D. Wechsler memory scale-revised. San Antonio: Psychological Corporation; 1987.

32.

Karakaş S. BİLNOT Bataryası El Kitabı: Nöropsikolojik Testler için Araştırma ve Geliştirme Çalışmaları. 1. Baskı. Ankara: Dizayn Ofset; 2004.

33.

Tabachnick BG, Fidell LS, Ullman JB. Using multivariate statistics, vol. 5. Boston: Pearson; 2007.

34.

Green MJ, Matheson SL, Shepherd A, Weickert CS, Carr VJ. Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. Mol Psychiatry. 2011;16(9):960–72. https://doi.org/10.1038/mp.2010.88.CrossRefPubMed

35.

Pedrini M, Chendo I, Grande I, Lobato MI, Belmonte-de-Abreu PS, Lersch C, et al. Serum brain-derived neurotrophic factor and clozapine daily dose in patients with schizophrenia: a positive correlation. Neurosci Lett. 2011;491(3):207–10. https://doi.org/10.1016/j.neulet.2011.01.039.CrossRefPubMed

36.

Vinogradov S, Fisher M, Holland C, Shelly W, Wolkowitz O, Mellon SH. Is serum brain-derived neurotrophic factor a biomarker for cognitive enhancement in schizophrenia? Biol Psychiatry. 2009;66(6):549–53. https://doi.org/10.1016/j.biopsych.2009.02.017.CrossRefPubMedPubMedCentral

37.

Lima Giacobbo B, Doorduin J, Klein HC, Dierckx RAJO, Bromberg E, de Vries EFJ. Brain-derived neurotrophic factor in brain disorders: focus on neuroinflammation. Mol Neurobiol. 2019;56(5):3295–312. https://doi.org/10.1007/s12035-018-1283-6.CrossRefPubMed

38.

Miranda M, Morici JF, Zanoni MB, Bekinschtein P. Brain-derived neurotrophic factor: a key molecule for memory in the healthy and the pathological brain. Front Cell Neurosci. 2019;13(363). https://doi.org/10.3389/fncel.2019.00363.

39.

Zakharyan R, Atshemyan S, Gevorgyan A, Boyajyan A. Nerve growth factor and its receptor in schizophrenia. BBA Clin. 2014;1:24–9. https://doi.org/10.1016/j.bbacli.2014.05.001.CrossRefPubMedPubMedCentral

40.

Tang X, Neckel ND, Schramm LP. Locations and morphologies of sympathetically correlated neurons in the T10 spinal segment of the rat. Brain Res. 2003;976(2):185–93. https://doi.org/10.1016/S0006-8993(03)02601-5.CrossRefPubMed

41.

Neugebauer K, Hammans C, Wensing T, Kumar V, Grodd W, Mevissen L, et al. Nerve growth factor serum levels are associated with regional gray matter volume differences in schizophrenia patients. Front Psychiatry. 2019;10(275). https://doi.org/10.3389/fpsyt.2019.00275.

42.

Tunca Z, Kıvırcık Akdede B, Özerdem A, Alkın T, Polat S, Ceylan D, et al. Diverse glial cell line-derived neurotrophic factor (GDNF) support between mania and schizophrenia: a comparative study in four major psychiatric disorders. Eur Psychiatry. 2015;30(2):198–204. https://doi.org/10.1016/j.eurpsy.2014.11.003.CrossRefPubMed

43.

Dietz AG, Goldman SA, Nedergaard M. Glial cells in schizophrenia: a unified hypothesis. Lancet Psychiatry. 2020;7(3):272–81. https://doi.org/10.1016/S2215-0366(19)30302-5.CrossRefPubMed

44.

Mohammadi A, Rashidi E, Amooeian VG. Brain, blood, cerebrospinal fluid, and serum biomarkers in schizophrenia. Psychiatry Res. 2018;265:25–38. https://doi.org/10.1016/j.psychres.2018.04.036.CrossRefPubMed

45.

Sahiner A, Buzkan G. An application of fuzzy goal programming to a specific diet problem. J Nat Appl Sci. 2010;14(2):124-33.

46.

Ünal S. Şizofrenide bilişsel işlev bozuklukları ve belirti oluşumu ile ilişkisi. Anadolu Psikiyatri Derg. 2003;4:46–53.

47.

Fioravanti M, Bianchi V, Cinti ME. Cognitive deficits in schizophrenia: an updated metanalysis of the scientific evidence. BMC Psychiatry. 2012;12(1):64. https://doi.org/10.1186/1471-244X-12-64.CrossRefPubMedPubMedCentral

48.

Sasi M, Vignoli B, Canossa M, Blum R. Neurobiology of local and intercellular BDNF signaling. Pflugers Arch. 2017;469(5–6):593–610. https://doi.org/10.1007/s00424-017-1964-4.CrossRefPubMedPubMedCentral

49.

Ahmed AO, Mantini AM, Fridberg DJ, Buckley PF. Brain-derived neurotrophic factor (BDNF) and neurocognitive deficits in people with schizophrenia: a meta-analysis. Psychiatry Res. 2015;226(1):1–13. https://doi.org/10.1016/j.psychres.2014.12.069.CrossRefPubMed

50.

Nelson HE, Pantelis C, Carruthers K, Speller J, Baxendale S, Barnes TRE. Cognitive functioning and symptomatology in chronic schizophrenia. Psychol Med. 1990;20(2):357–65. https://doi.org/10.1017/S0033291700017670.CrossRefPubMed

51.

Sofroniew MV, Howe CL, Mobley WC. Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci. 2001;24(1):1217–81. https://doi.org/10.1146/annurev.neuro.24.1.1217.CrossRefPubMed

52.

Aarao TLS, et al. Nerve growth factor and pathogenesis of leprosy: review and update. Front Immunol. 2018;9:939. https://doi.org/10.3389/fimmu.2018.00939.CrossRefPubMedPubMedCentral

Title: BDNF, GDNF, NGF and Klotho levels and neurocognitive functions in acute term of schizophrenia
Authors: Betul Aslan Turkmen
Esra Yazici
Derya Guzel Erdogan
Mehmet Akif Suda
Ahmet Bulent Yazici
Publication date: 01-12-2021
Publisher: BioMed Central
Keyword: Schizophrenia
Published in: BMC Psychiatry / Issue 1/2021
Electronic ISSN: 1471-244X
DOI: https://doi.org/10.1186/s12888-021-03578-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

BDNF, GDNF, NGF and Klotho levels and neurocognitive functions in acute term of schizophrenia

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Exploring low grade inflammation by soluble urokinase plasminogen activator receptor levels in schizophrenia: a sex-dependent association with depressive symptoms

Longitudinal relationships among problematic mobile phone use, bedtime procrastination, sleep quality and depressive symptoms in Chinese college students: a cross-lagged panel analysis

Locus of control moderates the association of COVID-19 stress and general mental distress: results of a Norwegian and a German-speaking cross-sectional survey

Correction to: Efficacy and acceptability of parent-only group cognitive behavioral intervention for treatment of anxiety disorder in children and adolescents: a meta-analysis of randomized controlled trials

Suicidal behaviors and attention deficit hyperactivity disorder (ADHD): a cross-sectional study among Chinese medical college students

Correction to: Adherence among HIV-positive injection drug users undergoing methadone treatment in Taiwan